American Century Companies Inc. Increases Stock Holdings in Biogen Inc. $BIIB

American Century Companies Inc. boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 34.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 81,253 shares of the biotechnology company’s stock after buying an additional 20,778 shares during the period. American Century Companies Inc. owned approximately 0.06% of Biogen worth $10,205,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of BIIB. AQR Capital Management LLC increased its position in Biogen by 153.6% during the first quarter. AQR Capital Management LLC now owns 1,368,842 shares of the biotechnology company’s stock valued at $187,258,000 after acquiring an additional 829,150 shares during the last quarter. AustralianSuper Pty Ltd boosted its stake in shares of Biogen by 85.9% during the 2nd quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock worth $92,863,000 after purchasing an additional 341,719 shares during the period. Vanguard Group Inc. grew its holdings in Biogen by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 17,032,839 shares of the biotechnology company’s stock valued at $2,330,774,000 after purchasing an additional 283,964 shares during the last quarter. State of Michigan Retirement System grew its holdings in Biogen by 633.7% during the 2nd quarter. State of Michigan Retirement System now owns 291,303 shares of the biotechnology company’s stock valued at $36,585,000 after purchasing an additional 251,600 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Biogen by 1,036.1% in the 2nd quarter. Acadian Asset Management LLC now owns 199,462 shares of the biotechnology company’s stock worth $25,044,000 after purchasing an additional 181,905 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

Shares of BIIB opened at $181.98 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. The company has a 50 day moving average price of $157.91 and a 200-day moving average price of $141.65. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $185.17. The stock has a market capitalization of $26.70 billion, a PE ratio of 16.59, a PEG ratio of 1.52 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. Biogen’s revenue was up 2.8% compared to the same quarter last year. During the same period last year, the company posted $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Equities analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BIIB. Sanford C. Bernstein boosted their target price on Biogen from $155.00 to $157.00 and gave the company a “market perform” rating in a research report on Monday, November 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday. Guggenheim upped their price objective on Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Royal Bank Of Canada decreased their target price on Biogen from $217.00 to $210.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Finally, Wells Fargo & Company boosted their target price on shares of Biogen from $140.00 to $155.00 in a research note on Friday, October 31st. Ten analysts have rated the stock with a Buy rating and seventeen have given a Hold rating to the company. According to data from MarketBeat.com, Biogen currently has an average rating of “Hold” and an average price target of $179.73.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.